

## Appendix 3Y

### Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Aroa Biosurgery Limited</b>
<b>ARBN</b>	<b>638 867 473</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Brian Ward
<b>Date of last notice</b>	17 June 2025

#### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
<b>Date of change</b>	23 July 2025

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held prior to change</b>	<b>Indirect</b> <i>Mr Brian Ward &amp; Mrs Tracey Ward &amp; Mr Thomas Ward &lt;Arawai No 2 A/C&gt;</i> 33,125,800 Fully Paid Ordinary Shares  3,132,525 Options exercisable at \$0.75 expiring 23 July 2025  649,695 Options exercisable at \$1.165 expiring on 13 November 2027  254,972 Options exercisable at \$1.165 expiring 29 February 2028  453,206 Options exercisable at \$Nil expiring 29 February 2028  961,255 Performance Rights expiring 1 August 2027
<b>Class</b>	Options exercisable at \$0.75 expiring 23 July 2025
<b>Number acquired</b>	Nil
<b>Number disposed</b>	3,132,525
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil
<b>No. of securities held after change</b>	<b>Indirect</b> <i>Mr Brian Ward &amp; Mrs Tracey Ward &amp; Mr Thomas Ward &lt;Arawai No 2 A/C&gt;</i> 33,125,800 Fully Paid Ordinary Shares  649,695 Options exercisable at \$1.165 expiring on 13 November 2027  254,972 Options exercisable at \$1.165 expiring 29 February 2028  453,206 Options exercisable at \$Nil expiring 29 February 2028  961,255 Performance Rights expiring 1 August 2027
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Lapse due to expiry of options

**Part 2 – Change of director's interests in contracts**

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

+ See chapter 19 for defined terms.

For personal use only